Abstract
Beta2-microglobulin (β2-MG) is a pharmacodynamic marker of interferon-β activity in multiple sclerosis (MS). Its role in the natural course of the disease is not fully known. We analyzed the spontaneous fluctuation of β2-MG in free-treatment MS patients during a short-time course to quantify β2-MG as a marker of disease activity/ progression. Thirty MS patients were clinically assessed and imaged monthly over a 3-month period. Sera were collected concomitantly for the evaluation of β2-MG, by means of an enzyme-linked immunosorbent assay. Sera from 20 healthy individuals (HI) were drawn and used as controls. The Mann-Whitney test was used when appropriate and time effect on radiological and biological measures was assessed by means of the random effect models. Eight (26.7%) patients experienced a clinical relapse but three (10%) required steroid treatment. A reduction in the contrast-enhancing lesion load (P = 0.02) and a trend (P = 0.07) toward a decrease in brain parenchyma fraction were observed. Baseline levels of β2-MG were similar in patients and HI. Patients' β2-MG values increased over the 3-month time period (P = 0.05) but did not exceed those detected in HI at any time point. These results failed to demonstrate the validity of β2-MG as a surrogate marker of disease in MS.
| Original language | English |
|---|---|
| Pages (from-to) | 455-460 |
| Number of pages | 6 |
| Journal | European Journal of Neurology |
| Volume | 11 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2004 |
Fingerprint
Keywords
- Beta2-microglobulin
- Biological marker
- Disease activity
- Gadolinium-enhancing lesions
- Inflammation
- Multiple sclerosis
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)
Cite this
β2-microglobulin serum level is not a marker of disease activity in multiple sclerosis. / Bagnato, F.; Zivadinov, R.; Cecchinelli, D.; Tancredi, A.; Grop, A.; Pierallini, A.; De Lena, C.; Prencipe, M.; Reale, G.; Zorzon, M.; Millefiorini, E.
In: European Journal of Neurology, Vol. 11, No. 7, 07.2004, p. 455-460.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - β2-microglobulin serum level is not a marker of disease activity in multiple sclerosis
AU - Bagnato, F.
AU - Zivadinov, R.
AU - Cecchinelli, D.
AU - Tancredi, A.
AU - Grop, A.
AU - Pierallini, A.
AU - De Lena, C.
AU - Prencipe, M.
AU - Reale, G.
AU - Zorzon, M.
AU - Millefiorini, E.
PY - 2004/7
Y1 - 2004/7
N2 - Beta2-microglobulin (β2-MG) is a pharmacodynamic marker of interferon-β activity in multiple sclerosis (MS). Its role in the natural course of the disease is not fully known. We analyzed the spontaneous fluctuation of β2-MG in free-treatment MS patients during a short-time course to quantify β2-MG as a marker of disease activity/ progression. Thirty MS patients were clinically assessed and imaged monthly over a 3-month period. Sera were collected concomitantly for the evaluation of β2-MG, by means of an enzyme-linked immunosorbent assay. Sera from 20 healthy individuals (HI) were drawn and used as controls. The Mann-Whitney test was used when appropriate and time effect on radiological and biological measures was assessed by means of the random effect models. Eight (26.7%) patients experienced a clinical relapse but three (10%) required steroid treatment. A reduction in the contrast-enhancing lesion load (P = 0.02) and a trend (P = 0.07) toward a decrease in brain parenchyma fraction were observed. Baseline levels of β2-MG were similar in patients and HI. Patients' β2-MG values increased over the 3-month time period (P = 0.05) but did not exceed those detected in HI at any time point. These results failed to demonstrate the validity of β2-MG as a surrogate marker of disease in MS.
AB - Beta2-microglobulin (β2-MG) is a pharmacodynamic marker of interferon-β activity in multiple sclerosis (MS). Its role in the natural course of the disease is not fully known. We analyzed the spontaneous fluctuation of β2-MG in free-treatment MS patients during a short-time course to quantify β2-MG as a marker of disease activity/ progression. Thirty MS patients were clinically assessed and imaged monthly over a 3-month period. Sera were collected concomitantly for the evaluation of β2-MG, by means of an enzyme-linked immunosorbent assay. Sera from 20 healthy individuals (HI) were drawn and used as controls. The Mann-Whitney test was used when appropriate and time effect on radiological and biological measures was assessed by means of the random effect models. Eight (26.7%) patients experienced a clinical relapse but three (10%) required steroid treatment. A reduction in the contrast-enhancing lesion load (P = 0.02) and a trend (P = 0.07) toward a decrease in brain parenchyma fraction were observed. Baseline levels of β2-MG were similar in patients and HI. Patients' β2-MG values increased over the 3-month time period (P = 0.05) but did not exceed those detected in HI at any time point. These results failed to demonstrate the validity of β2-MG as a surrogate marker of disease in MS.
KW - Beta2-microglobulin
KW - Biological marker
KW - Disease activity
KW - Gadolinium-enhancing lesions
KW - Inflammation
KW - Multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=3843089602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3843089602&partnerID=8YFLogxK
U2 - 10.1111/j.1468-1331.2004.00808.x
DO - 10.1111/j.1468-1331.2004.00808.x
M3 - Article
C2 - 15257683
AN - SCOPUS:3843089602
VL - 11
SP - 455
EP - 460
JO - European Journal of Neurology
JF - European Journal of Neurology
SN - 1351-5101
IS - 7
ER -